Sosei Group
Sosei Group Corporation is an international biopharmaceutical company based in Japan that focuses on discovering and developing innovative therapies for various medical conditions, including Alzheimer's disease, schizophrenia, cancer, migraine, addiction, and metabolic diseases. The company leverages advanced platform technologies, such as GPCR structure-based drug design, peptide platforms, and nanotechnology, to create a diverse product pipeline with significant therapeutic potential. Sosei Group has successfully partnered in the development and commercialization of three medicines, including two treatments for chronic obstructive pulmonary disease and an emergency contraceptive, which contribute to stable revenue streams and allow for continued growth in its operations.
MiNA Therapeutics Limited, a biotechnology company, engages in the design and development of small activating RNA medicines that restore normal function to patients' cells. The company’s products in pipeline includes MTL-CEBPA + Sorafebib for hepatocelluar carcinoma; and MTL-CEBPA + Pembrolizumab for advanced solid tumors. The company was incorporated in 2008 and is based in London, United Kingdom.
Jitsubo Co., Ltd. engages in the development, manufacturing, and commercialization of peptides that modify amino acid sequence for the creation of physical, chemical, and pharmacological properties. The company was founded in 2005 and is based in Koganei, Japan. As of December 26, 2014, Jitsubo Co., Ltd. operates as a subsidiary of Sosei Group Corporation.
Heptares Therapeutics Ltd. is a clinical-stage drug discovery company based in Welwyn Garden City, United Kingdom, founded in 2007. The company specializes in developing novel small-molecule medicines that target G protein-coupled receptors (GPCRs), a significant family of druggable targets associated with various human diseases. Heptares has pioneered a proprietary technology for producing purified, stabilized, and functional GPCRs, known as Stabilised Receptors (StaRs), which addresses a key challenge in drug development. Its research focuses on treatments for conditions such as Alzheimer's disease, ADHD, diabetes, schizophrenia, and migraines. Heptares maintains strategic collaborations with several organizations, including Pfizer and Kymab, to enhance its drug discovery efforts. As of 2015, Heptares operates as a subsidiary of Sosei Group Corporation.
Arakis Limited is engaged in the discovery and development of medicinal products, with a focus on inflammatory diseases and oncology adjunctive therapies. The company specializes in understanding cytokine and receptor-mediated mechanisms of disease, which informs its research and development efforts. Arakis identifies and commercializes product opportunities by exploring new clinical applications for established drugs and drug templates, as well as enhancing the performance of existing medicines. Through its innovative approach, Arakis aims to address unmet medical needs in the therapeutic areas of inflammatory disease and pain.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.